C12N 2740/10011
Retroviridae
C12N2740/10011 (Retroviridae) appears on 5,538 US grants and 8,614 published applications in this corpus.
Search patents in C12N- Granted patents
- 5,538
- Published applications
- 8,614
- Assignees
- 3,068
- Inventors
- 15,248
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 1 | 0 |
| 1978 | 4 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 10 | 0 |
| 1988 | 19 | 0 |
| 1989 | 23 | 0 |
| 1990 | 17 | 0 |
| 1991 | 34 | 0 |
| 1992 | 47 | 0 |
| 1993 | 45 | 0 |
| 1994 | 51 | 0 |
| 1995 | 52 | 0 |
| 1996 | 104 | 0 |
| 1997 | 178 | 0 |
| 1998 | 225 | 0 |
| 1999 | 195 | 0 |
| 2000 | 186 | 0 |
| 2001 | 185 | 40 |
| 2002 | 161 | 221 |
| 2003 | 162 | 347 |
| 2004 | 127 | 288 |
| 2005 | 93 | 286 |
| 2006 | 129 | 277 |
| 2007 | 116 | 191 |
| 2008 | 105 | 238 |
| 2009 | 148 | 239 |
| 2010 | 120 | 275 |
| 2011 | 122 | 237 |
| 2012 | 129 | 221 |
| 2013 | 112 | 173 |
| 2014 | 149 | 234 |
| 2015 | 148 | 229 |
| 2016 | 158 | 292 |
| 2017 | 163 | 285 |
| 2018 | 206 | 336 |
| 2019 | 226 | 407 |
| 2020 | 221 | 401 |
| 2021 | 203 | 475 |
| 2022 | 220 | 577 |
| 2023 | 223 | 541 |
| 2024 | 242 | 702 |
| 2025 | 256 | 656 |
| 2026 | 212 | 446 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/16011Human immunodeficiency virus, hivIndexing code3,789
- C12N 2740/15011Lentivirus, not hivIndexing code1,379
- C12N 2740/13011GammaretrovirusIndexing code790
- C12N 2740/10041Use of virus, viral particle or viral elements as a vectorIndexing code264
- C12N 2740/14011DeltaretrovirusIndexing code155
- C12N 2740/10022New viral proteins or individual genes, new structural or functional aspects ofIndexing code128
- C12N 2740/11011AlpharetrovirusIndexing code104
- C12N 2740/10051Methods of production or purification of viral materialIndexing code58
All 19 subgroupsShow fewer
- C12N 2740/17011SpumavirusIndexing code40
- C12N 2740/12011BetaretrovirusIndexing code36
- C12N 2740/10034Use of virus or viral component as vaccineIndexing code26
- C12N 2740/10023Virus like particles [vlp]Indexing code25
- C12N 2740/10021Viruses as suchIndexing code24
- C12N 2740/10071Demonstrated in vivo effectIndexing code13
- C12N 2740/10061Methods of inactivation or attenuationIndexing code9
- C12N 2740/10032Use of virus as therapeutic agent, other than vaccineIndexing code8
- C12N 2740/10033Use of viral protein as therapeutic agent other than vaccineIndexing code3
- C12N 2740/10031Uses of virus other than therapeutic or vaccineIndexing code0
- C12N 2740/10088For redistributionIndexing code0
Recent patents
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Polypeptide exhibiting fluorescent properties and use for same6 Oct 2026US 12,753,213 B2Riken
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- Composition for inducing direct cross differentiation of somatic cell into motor neuron, and method for using same6 Oct 2026US 12,753,385 B2Unist (Ulsan National Institute of Science and Technology)
- Immortalized keratinocytes, lentivirus for keratinocyte immortalization, and methods of use6 Oct 2026US 12,753,388 B2Regents of the University of Minnesota
- Materials and methods for increasing immune responses within a mammal8 Oct 2026US 2026/0306668 A1Mayo Foundation for Medical Education and Research
- Hybrid transient transfection using transposase for high yield product production8 Oct 2026US 2026/0308275 A1Lonza Biologics PLC
- Genetically engineered cd4 t-cells for in situ synthesis of proteins8 Oct 2026US 2026/0308515 A1SRI International
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
- Method for producing high-titer viral vector8 Oct 2026US 2026/0308534 A1Kaneka Corporation
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Delivery of exogenous DNA sequences in a mammal1,218US 5,580,859 AVical Incorporated · 1996
- Induction of a protective immune response in a mammal by injecting a DNA sequence885US 5,589,466 AVical Incorporated · 1996
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997